Abstract: The present invention provides a method for treating Alzheimer's Disease using a xanomeline transdermal formulation. The invention provides desired transdermal xanomeline patch formulations.

Abstract: A matrix for containing drugs for transdermal delivery systems is disclosed. The matrix formed of a skin-adhesive acrylate copolymer, attains high rates of drug delivery without the addition of drug delivery rate enhancers. In preferred embodiments the matrix is used to administer steroids, in particular estradiol.

Abstract: The invention relates to a plaster for transdermal application with an outer covering or backing layer, a self-adhesive matrix or a reservoir and a removable protective liner or release layer, the matrix or the reservoir containing tacrine and selegiline (optionally in the form of their pharmaceutically compatible salts) as active substance.

Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

Abstract: Skin care compositions and methods are provided for improving the appearance of skin affected by aging, photodamage and/or oxidative stress. Specifically, adhesive materials containing cosmetically active ingredients, e.g., one or more antioxidants such as Vitamins A, C and/or E, or moisturizers are applied in concentrated dry powdered form to target areas including the frownline area of the forehead, the front of the neck, the crows-feet area near the eyes, the upper lip and the nasolabial area using a transdermal patch having an acidity approximating human skin acidity of 5.5, preferably by an appropriate ratio of ascorbic acid and ascorbate salts.

Abstract: A novel device and method for delivering a liquid containing an active ingredient to a treatment site on the skin is disclosed. The device is useful for treating lesions or abnormal skin features such as corns, warts, calluses, bunions, actinic keratoses and hard hyperkeratotic skin as is often found on the face, arms, legs or feet.

Abstract: This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Abstract: This invention provides monolithic matrix formulations for transdermal administration of molsidomine. The device includes a copolymer of 2-ethylhexyl acrylate, 2-hydroxyethylmethacrylate, and methacrylic acid. The invention also provides transdermal devices having a monolithic matrix made using such a formulation in combination with an active ingredient and a vehicle or vehicle formulation.

Abstract: A permanent-wave treatment method which can give a permanent-wave comfortably without using a cap or a turban, and a treatment auxiliary agent used in this method. The permanent-wave treatment method comprises a winding step of applying permanent-wave treatment liquid to hair and winding the hair around rollers, and a liquid drop prevention step of sprinkling a powdery treatment auxiliary agent on the wound hair so as to prevent the permanent-wave treatment liquid from dropping. The treatment auxiliary agent comprises powder which adsorbs or partially dissolves in permanent-wave treatment liquid, and serves to increase the viscosity of the powder-sprinkled permanent-wave treatment liquid and prevent the permanent-wave treatment liquid from dropping.

Abstract: A pressure sensitive adhesive transdermal hormone delivery system is provided comprised of (1) a macromer reinforced (meth)acrylic ester base copolymer, and (2) a pharmacologically active agent in homogeneous admixture with said macromer-reinforced base copolymer, wherein the macromer contains hydrophilic repeat units

Abstract: A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C.sub.6 to C.sub.22 fatty acid esters of a lactic acid salt. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant contained in a penetration-enhancing vehicle comprising, 0.25 to 50% w. of the fatty acid ester of a lactic acid salt enhancer in a suitable pressure sensitive adhesive carrier vehicle formed from and aqueous emulsion based pressure sensitive adhesive.

Abstract: A method of adding a medicament (or other added ingredient) to animal feed pellets is described, in which the medicament is contained in a cohesive gel which is mixed with the feed pellets. The gel coats the pellets substantially homogeneously, and leaves little contamination of the mixing vessel.

Abstract: Transdermal patches are disclosed, including a backing layer, a liner layer, and a monolithic adhesive and drug-containing layer between the backing layer and the liner layer. The drug-containing adhesive layer includes polyisobutylene, a plasticizer for the polyisobutylene in which the ratio of the plasticizer and the polyisobutylene is less than about 0.8 and at least 5% of a filler. The drug so utilized is moderately soluble in the plasticizer.

Abstract: A controlled release tablet including a pharmaceutical agent and an excipient. The excipient includes at least about 60% of a water swellable polymer and a lubricant. The water swellable polymer is chosen such that the swelling rate of the polymer is equal to the dissolution rate of the swollen polymer. The excipient may also include such other ingredients as diluents, fillers, binders, solubilizers, emulsifiers, and other pharmacologically inactive compounds. The polymer is chosen with the pharmaceutical agent in mind such that the tablet will be fully dissolved at the same time that the last of the pharmaceutical agent is released.

Abstract: Pharmaceutical gel formulations for topical drug delivery include drug, colloidal silicon dioxide, triacetin and, preferably, propylene glycol. The gel formulations are well suited for topical delivery of the drug 4-amino-2-ethoxymethyl-.alpha.,.alpha.-dimethyl-1H-imidazo?4,5-c!quinoline -1-ethanol, which when applied topically induces cytokines, such as interferon and tumor necrosis factor, locally in the skin or mucous membranes of a mammal. The gel formulations are also well-suited for topical delivery of drugs for treatment of diseases involving skin and/or mucosal lesions because the gel formulations do not need to include irritating components.

Abstract: A transdermal therapeutic system for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins is characterized in that it has a pharmaceutical formulation with an active substance combination consisting of at least one parasympathomimetically active substance and at least one parasympatholytically active substance.

Abstract: Dosage forms for the transdermal administration of apomorphine are described. The dosage forms are water-soluble gel compositions that contain apomorphine, optionally together with a permeation enhancer, or transdermal patches.

Abstract: Novel drug delivery devices, methods and therapeutic compositions are described for treating viral and microbial infections and wasting syndromes in an animal, including a human patient. According to the invention, a polar compound such as dimethylformamide or dimethylsulfoxide is administered to a patient in need of treatment, preferably by a transdermal route. The invention further provides a vaccine prepared from antibodies harvested from the body of a patient treated by the method of the invention for a viral infection.

Abstract: The device according to this invention is provided to reduce the trauma which can be caused by an open wound such as that caused after childbirth and in particular to reduce the trauma of an open wound in the perineal and/or rectal area which can be painful and uncomfortable to a person having experienced childbirth. The device comprises a housing having a gel-like material therein which can be cooled prior to application to the area and said material has a high thermal capacity so that when the device is applied a cooling effect is created, an occluding effect of the open wound is provided and furthermore a cushioning effect on the area surrounding the wound is also provided thereby allowing the device to be used comfortably and also to improve the comfort of the person to whom the same is applied.

Abstract: The present invention is related to prostheses, their methods of manufacture and methods for repairing vascular lesions using such prostheses. Natural polymers such as collagen are processed and fabricated to form tubular resorbable vascular wound dressings with unique physico-chemical and mechanical properties for repairing selected vascular segments, and for delivering therapeutic agents at selected sites within vessels and at the anastomoses.